Curaleaf Holdings reported $340.1 million in net revenue for the second quarter of 2026, an increase of 10% from the same period last year, while the company recorded net income of $12.5 million.
Revenue increased from $310.6 million in the second quarter of 2025 and was up 5% compared with $324.2 million during the first quarter of 2026.
Curaleaf generated $169.9 million in gross profit, representing a gross margin of 50%. That compares with gross profit of $153.1 million and a margin of 49.3% during the same quarter last year.
Adjusted earnings before interest, taxes, depreciation and amortization totaled $70.1 million, up from $67.9 million a year earlier. However, Curaleaf’s adjusted EBITDA margin declined from 21.9% to 20.6%.
“Our second quarter results reinforce that our ‘Built for Growth’ strategy, a disciplined framework focused on customer centricity, brand building, and operational excellence is gaining traction across the business,” said Curaleaf Chairman and CEO Boris Jordan.
Jordan said the company’s domestic and international segments grew by 7% and 26%, respectively, compared with the second quarter of 2025.
Domestic revenue reached $288.7 million, including $224.4 million in retail revenue and $64 million in wholesale revenue. Domestic revenue totaled $269.7 million during the same period last year.
International revenue increased from $40.9 million to $51.4 million. The international total included $16.4 million in retail revenue, $31.9 million in wholesale revenue and $3.1 million in management fee income.
Curaleaf reported income from continuing operations of $4.2 million before interest and other expenses. The company recorded a $26.3 million loss before income taxes, but a $38.8 million income tax benefit resulted in net income from continuing operations of $12.5 million.
That compares with a net loss attributable to Curaleaf of $53.2 million during the second quarter of 2025.
For the first six months of 2026, Curaleaf generated $664.3 million in revenue, an increase of 8% from $617.2 million during the same period last year. Six-month net income attributable to the company totaled $82.3 million, compared with a loss of $114.2 million in 2025.
Adjusted EBITDA for the first half of the year was $133.5 million, remaining nearly unchanged from $134 million a year earlier. The adjusted EBITDA margin declined from 21.7% to 20.1%.
Curaleaf generated $50.3 million in operating cash flow from continuing operations during the six-month period. After $32.9 million in capital expenditures, the company reported free cash flow of $17.4 million.
The company ended June with $107 million in cash and restricted cash and approximately $611.5 million in outstanding debt.
During the quarter, Curaleaf expanded its Florida retail footprint to 73 dispensaries by opening locations in Jacksonville Beach and Fernandina Beach. Two additional dispensaries opened after the quarter ended, bringing the company’s Florida total to 75 and its nationwide operated and managed retail footprint to 176.
Curaleaf also launched its Dark Heart premium marijuana flower brand in 11 states and completed its purchase of the remaining 45% interest in German subsidiary Four20 Pharma. The transaction increased Curaleaf’s ownership of its international division to 100%.
The company said it has applied to register all of its medical marijuana cultivation, processing and dispensing locations with the Drug Enforcement Administration.
Sponsors:
